Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 4
1978 7
1979 21
1980 34
1981 40
1982 50
1983 67
1984 90
1985 86
1986 68
1987 60
1988 63
1989 78
1990 94
1991 77
1992 77
1993 67
1994 76
1995 66
1996 68
1997 61
1998 44
1999 66
2000 61
2001 41
2002 45
2003 31
2004 28
2005 32
2006 19
2007 25
2008 22
2009 24
2010 13
2011 19
2012 17
2013 23
2014 24
2015 24
2016 16
2017 12
2018 16
2019 14
2020 15
2021 19
2022 17
2023 23
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

1,910 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
Cersosimo RJ, Bromer R, Licciardello JT, Hong WK. Cersosimo RJ, et al. Pharmacotherapy. 1983 Sep-Oct;3(5):259-74. doi: 10.1002/j.1875-9114.1983.tb03269.x. Pharmacotherapy. 1983. PMID: 6359081 Review.
Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. ...Vindesine will be a positive addition to the antineoplastic armamentarium. ...
Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. ...Vindesine will be a positive addition to t …
Vindesine in the treatment of leukaemia.
Gökbuget N, Hoelzer D. Gökbuget N, et al. Leuk Lymphoma. 1997 Aug;26(5-6):497-506. doi: 10.3109/10428199709050886. Leuk Lymphoma. 1997. PMID: 9389357 Review.
In myeloid leukaemias, while vindesine appears to have a limited role in ANLL, it may be useful for the palliative treatment of CML blast crisis. In the future, new synergistic combinations, incorporating vindesine with for example, methotrexate or edatrexate, may b …
In myeloid leukaemias, while vindesine appears to have a limited role in ANLL, it may be useful for the palliative treatment of CML b …
Vindesine tragedy.
Cohen MR. Cohen MR. Nursing. 2009 Mar;39(3):12. doi: 10.1097/01.NURSE.0000347050.21740.8c. Nursing. 2009. PMID: 19247102 No abstract available.
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Yamamoto N, et al. J Clin Oncol. 2010 Aug 10;28(23):3739-45. doi: 10.1200/JCO.2009.24.5050. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625120 Clinical Trial.
PATIENTS AND METHODS: Eligible patients received the following treatments: A (control), four cycles of mitomycin (8 mg/m(2) on day 1)/vindesine (3 mg/m(2) on days 1, 8)/cisplatin (80 mg/m(2) on day 1) plus TRT 60 Gy (treatment break for 1 week); B, weekly irinotecan (20 mg …
PATIENTS AND METHODS: Eligible patients received the following treatments: A (control), four cycles of mitomycin (8 mg/m(2) on day 1)/vin …
Is there a role for vindesine in the treatment of non-small cell lung cancer?
Sørensen JB, Hansen HH. Sørensen JB, et al. Invest New Drugs. 1993 May-Aug;11(2-3):103-33. doi: 10.1007/BF00874146. Invest New Drugs. 1993. PMID: 8262725 Review.
Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. The literature on vindesine in the treatment of non-small cell lung cancer has been reviewed and all aspects of vindesine treatment in t …
Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. The litera …
Vindesine for psoriasis?
Hardi R, Slavik M. Hardi R, et al. Lancet. 1981 Apr 4;1(8223):773. doi: 10.1016/s0140-6736(81)92639-8. Lancet. 1981. PMID: 6110967 No abstract available.
The role of vindesine in oncology--recommendations after 10 years' experience.
Dancey J, Steward WP. Dancey J, et al. Anticancer Drugs. 1995 Oct;6(5):625-36. doi: 10.1097/00001813-199510000-00001. Anticancer Drugs. 1995. PMID: 8845472 Review.
Vindesine, a vinca alkaloid derived from vinblastine, has been examined for activity against a variety of solid and hematological malignancies. ...It has limited activity in breast cancer (average 16% response rate) and does not appear to improve outcome when combined with …
Vindesine, a vinca alkaloid derived from vinblastine, has been examined for activity against a variety of solid and hematological mal …
Role of vindesine in induction chemotherapy in locally-advanced non-small-cell lung cancer.
Fischer JR, Drings P. Fischer JR, et al. J Cancer Res Clin Oncol. 1998 Jan;124(1):4-9. doi: 10.1007/s004320050126. J Cancer Res Clin Oncol. 1998. PMID: 9498828 Review.
Clinical investigations have reported an improvement of survival in stage III NSCLC after induction chemotherapy by using different combinations of cytotoxic drugs. Vindesine ranks among the most active single agents in this disease and has been part of a number of combina …
Clinical investigations have reported an improvement of survival in stage III NSCLC after induction chemotherapy by using different combinat …
Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, et al. Einhorn LH, et al. J Clin Oncol. 1986 Jul;4(7):1037-43. doi: 10.1200/JCO.1986.4.7.1037. J Clin Oncol. 1986. PMID: 3088219 Clinical Trial.
The objective response rate for cisplatin and vindesine was 27% v 20% for cisplatin, vindesine, and mitomycin C, and 14% for vindesine alone (P = .25 for cisplatin and vindesine v vindesine). ...The median survival time for vindesine was …
The objective response rate for cisplatin and vindesine was 27% v 20% for cisplatin, vindesine, and mitomycin C, and 14% for …
1,910 results